摘要
目的探讨急性心肌梗死(AMI)合并多支血管病变(MVD)患者经皮冠状动脉介入治疗(PCI)开通非梗死相关动脉(Non-IRA)的最佳时机。方法纳入AMI合并MVD患者357例,根据是否干预及干预Non-IRA的时机分为对照组(只干预罪犯血管且未择期开通Non-IRA)(n=117)、MV-PCI组(急诊PCI同时开通Non-IRA)(n=32)、0-7 d组(n=28)(排除MV-PCI患者)、8-30 d组(n=84)、31-60 d组(n=96),随访2年。比较各组基本临床资料、冠脉造影/PCI情况和2年内主要心血管不良事件(MACE)等。结果院内MACE发生率对照组最低(3.4%),其次为31-60 d组(4.2%),MV-PCI组最高(18.8%)(P=0.02)。随访MACE发生率对照组最高(59.8%)(P〈0.01)。累积MACE发生率31-60 d组最低(18.80%)(P〈0.01)。结论 PCI干预非梗死相关动脉能够改善预后;急诊PCI一次性完全血运重建风险较大;心肌梗死后31-60 d为干预AMI患者非梗死相关动脉的较理想时机。
Objective To explore the timing of percutaneous coronary intervention( PCI) for non-infarct-related artery( Non-IRA) in patients with acute myocardial infarction( AMI) and multi-vessel disease( MVD). Methods A total of 357 cases of AMI and MVD were divided into 5 groups according to whether and when they underwent PCI for NonIRA: control group( n = 117,who underwent PCI for culprit vessel only),MV-PCI group( n = 32,who underwent PCI simultaneously for both culprit vessel and Non-IRA),0-7d group( n = 28,who underwent PCI for Non-IRA within7 day); 8-30 d group( n = 84,who underwent PCI for Non-IRA within 8-30 days),31-60 d group( n = 96,who underwent PCI for Non-IRA within 31-60 days). All patients were followed up for 2 years. Clinical characteristics,data collected during surgery and major adverse cardiac event( MACE) were analyzed. Results The incidence of in-hospital MACE was the highest in the MV-PCI group( 18. 8%),the lowest in the control group( 3. 4%),and the second lowest in the 31-60 d group( P = 0. 02). The incidence of follow-up MACE was the highest in the control group( 59. 8%)( P〈0. 01),and the cumulative rate of MACE was the lowest in the 31-60 d group( 18. 80%)( P〈0. 01).Conclusion PCI of Non-IRA can improve the prognosis. Emergency PCI for simultaneous culprit vessel and Non-IRA is risky. It's advisable to choose PCI for Non-IRA within 31-60 days after AMI.
出处
《山东大学学报(医学版)》
CAS
北大核心
2016年第8期50-54,共5页
Journal of Shandong University:Health Sciences
关键词
心肌梗死
多支血管病变
非梗死相关动脉
经皮冠状动脉
预后
Myocardial infarction
Multivessel disease
Non-infarct-related artery
Percutaneous coronary
Prognosis